isirv Antiviral Group
AVG Home
AVG Webinar Series
AVG Webinar series You can listen to the recordings from the AVG webinars which have taken place to date via the links below: 25 October 2022: Treatments/Antiviral Therapeutics - link to the recording 24 January 2023: Antiviral Resistance - link to the recording 20 June 2023: The Present and Future of Treatment Oriented Surveillance - link to the recording 30 Oct 2023: Challenges and Promise of Clinical Trials for Respiratory Antivirals - link to the recording 2024 ISIRV Webinars 24 Jan If you missed the webinar on 24 Jan on 'RSV Vaccination in the Elderly Population' you can register and watch the recording via this link 20 March Register today for this webinar on 'Emerging Influenza and the Human-Animal Interface' via this link 29 May Webinar on ‘Recent antiviral developments for respiratory viral infections’ We’re delighted to announce that we’ll have 3 speakers on this webinar. Professor Bin Cao, China-Japan Friendship Hospital, Beijing, China will give an overview talk on ‘Recent Antiviral Developments for Respiratory Viral Infections in China'. Dr Tom Fletcher, Liverpool School of Tropical Medicine, Liverpool, UK who will speak on ‘IV favipirivir’ Dr Don Ganem, Via Nova Therapeutics, Oakland, CA, USA who will speak on 'VNT-101: A Novel, Orally Bioavailable Inhibitor of Influenza A Virus Targeting the Viral Nucleoprotein, NP' You can register now via this link
7th AVG Conference (in-person)
AVG Overview
The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More
Latest… Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo… read more Protective human antibodies against a conserved epitope in pre- and post- fusion influenza hemagglutinin… read more Oseltamivir May or May Not Reduce Hospitalizations… read more Prescription of anti-influenza drugs in Japan, 2014-2020: A retrospective study using open data from the national claims database … read more Influenza virus cell entry and targeted antiviral development … read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA
|
Quick links:
Contact AVG:Email:avg@isirv.org |